- 10 June
-
The Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region, a collective member of the Ural Biomedical Cluster, has participated in the CHEMTECH URAL, first specialised forum and exhibition, held from May 26 to 28 in the Ekaterinburg-EXPO International Exhibition Centre. The organization acted as an industry partner for the event, bringing together key players from the pharmaceutical and chemical sectors of the region at its joint booth.
- 10 June
-
Pharmaceutical Chemistry: Towards Full-Cycle Production round table discussion was held as part of the business program at ChemTech Ural 2026. Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, was the keynote speaker at the event.
- 10 June
-
Medsintez Plant, one of Russia's leading manufacturers of insulins and drugs for the therapy of socially significant diseases, traditionally participated in the 11th (32nd) National Congress of Endocrinologists with International Participation. The event, themed Personalized Medicine in Endocrinology: From Fundamental Science to Clinical Practice, took place from 26 to 29 May in Moscow.
- 10 June
-
In 2025, the Governor of the Sverdlovsk Region, Denis Vladimirovich Pasler, signed a decree awarding the Regional Head's Certificate of Honour to Alexey Borisovich Podkorytov, CEO of Medsintez Plant LLC.
- Home
- Cluster members
- As & Co Pharm group LLC
As & Co Pharm group LLC
The enterprise As & Co Pharm group LLC is the Ural pharmaceutical company Asco Pharm. The company is a portfolio project of the Ural Federal University (UrFU) Innovation Development Fund, UrFU Innovation Infrastructure and INNOPORT startup studio. Asco Pharm has been researching and developing medicines and dietary supplements for over 15 years. The flagship project of the company is the development of an innovative original drug for the prevention and treatment of osteoporosis, which is in the process of going through the necessary clinical and bureaucratic procedures. In this regard, in order to accelerate the commercialization of the project, the company, based on this drug, brought to the market an innovative dietary supplement REOCYTAN Calcium- Magnesium-D3. Even during the research period, the project showed excellent results, opening up a completely new approach in the fight against osteoporosis and calcium deficiency. The drug uses a patented formula that has no analogues in the world and an innovative technology for delivering calcium to bone tissue. The project has received great interest from the scientific community in Russia and abroad. With this project, the company won the largest business accelerator in the Urals of the Ural Federal University in 2018 And in 2020, Reocytan won the prestigious medical innovation competition held by TIPA in South Korea. Asco Pharm's portfolio also includes more than 20 developments at various stages: recovery after strokes and severe brain injuries, tissue repair after injuries or severe pathologies (heart failure, AECB, SARS, COVID, etc.) oncoprophylaxis technology, technology for removal of hepatitis B virus complicated by D, technology for preventing an autoimmune response in pneumonia of various etiologies, a line of products that suppress muscular dystrophy, etc.
The company is planning to bring several more brands to the market in the next few years.
Tel.: +7 (922)-115-30-63
E-mail: info@ascopharm.ru
www.ascopharm.ru
www.reocytan-calcium.com
